384 related articles for article (PubMed ID: 26165832)
1. An update on the use of lenalidomide for the treatment of multiple myeloma.
Zagouri F; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Pharmacother; 2015; 16(12):1865-77. PubMed ID: 26165832
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide: an update on evidence from clinical trials.
Dimopoulos MA; Terpos E
Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Syed YY
Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide in the treatment of multiple myeloma: a review.
Armoiry X; Aulagner G; Facon T
J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.
Bringhen S; Gay F; Pautasso C; Cerrato C; Boccadoro M; Palumbo A
Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1209-22. PubMed ID: 22862790
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide in multiple myeloma.
Kim Y; Schmidt-Wolf IG
Expert Rev Anticancer Ther; 2015 May; 15(5):491-7. PubMed ID: 25843431
[TBL] [Abstract][Full Text] [Related]
7. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
Richardson PG; Holstein SA; Schlossman RL; Anderson KC; Attal M; McCarthy PL
Expert Opin Pharmacother; 2017 Dec; 18(18):1975-1985. PubMed ID: 29172855
[TBL] [Abstract][Full Text] [Related]
9. United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma.
Davies F; Morris C; Bird J; Cook G; Williams C; Tighe J; Cavenagh J; Behrens J; Schey S; Morgan G;
Int J Lab Hematol; 2009 Apr; 31(2):119-31. PubMed ID: 19016917
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Weber DM; Chen C; Niesvizky R; Wang M; Belch A; Stadtmauer EA; Siegel D; Borrello I; Rajkumar SV; Chanan-Khan AA; Lonial S; Yu Z; Patin J; Olesnyckyj M; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2133-42. PubMed ID: 18032763
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide in multiple myeloma.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
[TBL] [Abstract][Full Text] [Related]
13. Role of thalidomide in the treatment of patients with multiple myeloma.
Morgan GJ; Davies FE
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S14-22. PubMed ID: 23827438
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience.
Soyer N; Patır P; Uysal A; Duran M; Ünal HD; Durusoy R; Tombuloğlu M; Şahin F; Töbü M; Vural F; Saydam G
Turk J Med Sci; 2018 Aug; 48(4):777-785. PubMed ID: 30119153
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide mode of action: linking bench and clinical findings.
Davies F; Baz R
Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
[TBL] [Abstract][Full Text] [Related]
16. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
Mariz JM; Esteves GV
Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide and lenalidomide in multiple myeloma.
Mazumder A; Jagannath S
Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
[TBL] [Abstract][Full Text] [Related]
18. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Morgan G
Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation.
McCormack PL
Drugs Aging; 2015 May; 32(5):409-18. PubMed ID: 25925941
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]